Literature DB >> 21805310

Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer.

Rosa Landwehr1, Natalia V Bogdanova, Natalia Antonenkova, Andreas Meyer, Michael Bremer, Tjoung-Won Park-Simon, Peter Hillemanns, Johann H Karstens, Detlev Schindler, Thilo Dörk.   

Abstract

SLX4 coordinates three structure-specific endonucleases in the DNA damage response. One subtype of Fanconi anaemia, FA-P, has recently been attributed to biallelic SLX4 gene mutations. To investigate whether monoallelic SLX4 gene defects play some role in the inherited component of breast cancer susceptibility, in this study we resequenced the whole SLX4 coding region and flanking untranslated sections in genomic DNA samples obtained from a total of 52 German or Byelorussian patients with familial breast cancer. Selected variants were subsequently screened by RFLP or TaqMan-based assays in an extended set of 965 German breast cancer cases and 985 healthy female controls. The resequencing study uncovered four new SLX4 missense substitutions, each of them in a single breast cancer patient. Three missense substitutions (p.V197A, p.G700R and p.R1034H) were not found in a subsequent screening of 240 additional breast cancer patients, while one missense substitution (p.R237Q) was more common and was detected in a total of 12 cases (1.3%) and seven controls (0.7%) in the Hannover breast cancer study. The rare missense substitution, p.G700R, resides in the conserved BTB domain and was in silico predicted to be pathogenic. Seven additional missense polymorphisms were correlated and formed one haplotype which was, however, neither associated with breast cancer risk nor with survival from breast cancer. In summary, this study did not reveal truncating or clearly pathogenic mutations, but unravelled four new unclassified missense variants at a low frequency. We conclude that there is no evidence for a major role of SLX4 coding variants in the inherited susceptibility towards breast cancer in German and Byelorussian patients, although very rare mutations such as the p.G700R substitution could make a minor contribution.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21805310     DOI: 10.1007/s10549-011-1681-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  12 in total

Review 1.  Genetic counseling for Fanconi anemia: crosslinking disciplines.

Authors:  Heather A Zierhut; Rebecca Tryon; Erica M Sanborn
Journal:  J Genet Couns       Date:  2014-09-20       Impact factor: 2.537

2.  Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.

Authors:  Maral Jamshidi; Marjanka K Schmidt; Thilo Dörk; Montserrat Garcia-Closas; Tuomas Heikkinen; Sten Cornelissen; Alexandra J van den Broek; Peter Schürmann; Andreas Meyer; Tjoung-Won Park-Simon; Jonine Figueroa; Mark Sherman; Jolanta Lissowska; Garrett Teoh Hor Keong; Astrid Irwanto; Marko Laakso; Sampsa Hautaniemi; Kristiina Aittomäki; Carl Blomqvist; Jianjun Liu; Heli Nevanlinna
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

3.  Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.

Authors:  Fabricio G Sousa; Renata Matuo; Sai-Wen Tang; Vinodh N Rajapakse; Augustin Luna; Chris Sander; Sudhir Varma; Paul H G Simon; James H Doroshow; William C Reinhold; Yves Pommier
Journal:  DNA Repair (Amst)       Date:  2015-02-11

4.  Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families.

Authors:  Gorka Ruiz de Garibay; Avellaneda Díaz; Belén Gaviña; Atocha Romero; Pilar Garre; Ana Vega; Ana Blanco; Alicia Tosar; Orland Díez; Pedro Pérez-Segura; Eduardo Díaz-Rubio; Trinidad Caldés; Miguel de la Hoya
Journal:  Eur J Hum Genet       Date:  2012-12-05       Impact factor: 4.246

5.  Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.

Authors:  Allison W Kurian; Emily E Hare; Meredith A Mills; Kerry E Kingham; Lisa McPherson; Alice S Whittemore; Valerie McGuire; Uri Ladabaum; Yuya Kobayashi; Stephen E Lincoln; Michele Cargill; James M Ford
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

6.  Sequencing analysis of SLX4/FANCP gene in Italian familial breast cancer cases.

Authors:  Irene Catucci; Mara Colombo; Paolo Verderio; Loris Bernard; Filomena Ficarazzi; Frederique Mariette; Monica Barile; Bernard Peissel; Elisa Cattaneo; Siranoush Manoukian; Paolo Radice; Paolo Peterlongo
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

7.  Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.

Authors:  Juana Fernández-Rodríguez; Francisco Quiles; Ignacio Blanco; Alex Teulé; Lídia Feliubadaló; Jesús Del Valle; Mónica Salinas; Angel Izquierdo; Esther Darder; Detlev Schindler; Gabriel Capellá; Joan Brunet; Conxi Lázaro; Miguel Angel Pujana
Journal:  BMC Cancer       Date:  2012-03-08       Impact factor: 4.430

8.  Assessment of SLX4 Mutations in Hereditary Breast Cancers.

Authors:  Sohela Shah; Yonghwan Kim; Irina Ostrovnaya; Rajmohan Murali; Kasmintan A Schrader; Francis P Lach; Kara Sarrel; Rohini Rau-Murthy; Nichole Hansen; Liyng Zhang; Tomas Kirchhoff; Zsofia Stadler; Mark Robson; Joseph Vijai; Kenneth Offit; Agata Smogorzewska
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

9.  Mutation analysis of the ERCC4/FANCQ gene in hereditary breast cancer.

Authors:  Sandra Kohlhase; Natalia V Bogdanova; Peter Schürmann; Marina Bermisheva; Elza Khusnutdinova; Natalia Antonenkova; Tjoung-Won Park-Simon; Peter Hillemanns; Andreas Meyer; Hans Christiansen; Detlev Schindler; Thilo Dörk
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

10.  Estrogen Aggravates Tumor Growth in a Diffuse Gastric Cancer Xenograft Model.

Authors:  Sunyi Lee; Kyoung Mee Kim; Seung Yeon Lee; Joohee Jung
Journal:  Pathol Oncol Res       Date:  2021-04-16       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.